论文部分内容阅读
目的:甘精胰岛素联合瑞格列奈治疗2型糖尿病临床疗效观察。方法:将我院2013年1月-2014年1月收治过的168例2型糖尿病患者随机分为研究组与对照组,其中研究组采用甘精胰岛素联合瑞格列奈治疗,对照组采用预混胰岛素治疗。16周后观察测试研究组与对照组的体质指数、血尿血红蛋白、血清尿酸水平以及胰岛素水平等情况。结果:两组患者治疗前后血尿血红蛋白、血清尿酸水平以及胰岛素水平差异均有统计学意义(P<0.05),两组患者治疗后总有效率、低血糖发生率差异均具有统计学意义(P<0.05)。结论:甘精胰岛素联合瑞格列奈治疗2型糖尿病,可获得较佳的临床疗效与安全性,在临床上值得推广应用。
Objective: To observe the curative effect of glargine and repaglinide on type 2 diabetes mellitus. Methods: A total of 168 type 2 diabetic patients treated in our hospital from January 2013 to January 2014 were randomly divided into study group and control group. The study group was treated with insulin glargine combined with repaglinide, while the control group Mixed insulin therapy. After 16 weeks, the body mass index, hematuria and hemoglobin, serum uric acid level and insulin level in the study group and the control group were observed. Results: Before and after treatment, the hemoglobin, serum uric acid level and insulin level in both groups were significantly different (P <0.05). There was significant difference between the two groups in the total effective rate and the incidence of hypoglycemia (P < 0.05). Conclusion: Glargine combined with repaglinide in type 2 diabetes mellitus can achieve better clinical efficacy and safety, which is worth popularizing in clinic.